| __timestamp | HUTCHMED (China) Limited | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 3243000 |
| Thursday, January 1, 2015 | 110777000 | 2472000 |
| Friday, January 1, 2016 | 156328000 | 2548000 |
| Sunday, January 1, 2017 | 175820000 | 19623000 |
| Monday, January 1, 2018 | 143944000 | 30421000 |
| Tuesday, January 1, 2019 | 160152000 | 32793999 |
| Wednesday, January 1, 2020 | 188519000 | 28304000 |
| Friday, January 1, 2021 | 258234000 | 620000 |
| Saturday, January 1, 2022 | 311103000 | 755000 |
| Sunday, January 1, 2023 | 384447000 | 1322000 |
Unlocking the unknown
In the dynamic world of pharmaceuticals, cost efficiency is a critical metric. Over the past decade, HUTCHMED (China) Limited and Viridian Therapeutics, Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, HUTCHMED's cost of revenue surged by over 430%, reflecting its aggressive expansion and operational scaling. In contrast, Viridian's cost of revenue exhibited a more volatile pattern, peaking in 2019 before a dramatic reduction in subsequent years. By 2023, HUTCHMED's cost of revenue was approximately 29 times that of Viridian's, highlighting a stark difference in operational scale and strategy. This divergence underscores the varied approaches companies take in managing costs amidst evolving market conditions. As investors and analysts look to the future, understanding these trends offers valuable insights into each company's strategic priorities and market positioning.
Cost of Revenue: Key Insights for GSK plc and Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Biogen Inc. and HUTCHMED (China) Limited
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and HUTCHMED (China) Limited
PTC Therapeutics, Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Research and Development: Comparing Key Metrics for HUTCHMED (China) Limited and Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.